Clinical Trial Update: Safety and Efficacy of SmithKline Beecham (GlaxoSmithKline [GSK]) Biologicals' Candidate Adjuvanted Vaccines (287615) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating the safety and efficacy of GlaxoSmithKline's adjuvanted hepatitis B vaccine candidate (287615) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• Adjuvanted vaccine candidate 287615

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis B Disease | Phase 1, Phase 2 | Status: COMPLETED